Jolly: The research and development work on the Parkinson's pipeline LY-N001 of Lingyi Biotech is ongoing
Jolly stated during an institutional research that the R&D work for Lingyi Biotech's Parkinson's pipeline LY-N001 is ongoing, and the main preclinical research has been completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with future goals of applying for IND in China and the U.S. and conducting clinical research and global market layout. Lingyi Biotech is a company focused on innovative drug development for single-gene genetic diseases, positioned to develop gene therapy drugs with differentiated advantages. The company increased its investment in Lingyi Biotech by 20 million yuan in April 2025
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments